Skip to main content
. Author manuscript; available in PMC: 2012 Apr 16.
Published in final edited form as: J Cardiovasc Transl Res. 2011 Mar 22;4(3):340–350. doi: 10.1007/s12265-011-9270-6

Fig. 4.

Fig. 4

Overview of “hit” to drug refinement. Once identified by screening, a “hit” is selected for optimization based on its pharmacological and pharmaceutical prospects, and improved through several rounds of dynamic medicinal chemistry. Ultimately this should result in drug-like leads that can be used for testing in animal models and as the basis for affinity reagents to study mechanism of action